These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22144293)

  • 1. In vivo enhancement in bioavailability of atazanavir in the presence of proton-pump inhibitors using mesoporous materials.
    Xia X; Zhou C; Ballell L; Garcia-Bennett AE
    ChemMedChem; 2012 Jan; 7(1):43-8. PubMed ID: 22144293
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations.
    Nso Roca AP; Larru B; Bellón JM; Mellado MJ; Ramos JT; González MI; Navarro ML; Muñoz-Fernández MÁ; José MI
    J Adolesc Health; 2011 Jan; 48(1):100-2. PubMed ID: 21185531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.
    Zhu L; Butterton J; Persson A; Stonier M; Comisar W; Panebianco D; Breidinger S; Zhang J; Bertz R
    Antivir Ther; 2010; 15(8):1107-14. PubMed ID: 21149917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
    Winston A; Bloch M; Carr A; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S
    J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use.
    Goicoechea M; Best B; Capparelli E; Caperna J; Ballard C; Haubrich R
    AIDS; 2006 Oct; 20(16):2127-8. PubMed ID: 17053363
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
    J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.
    Sahloff EG; Duggan JM
    Ann Pharmacother; 2006 Oct; 40(10):1731-6. PubMed ID: 16968825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
    Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
    Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Introduction. Usefulness of atazanavir in the treatment of patients infected by human immunodeficiency virus].
    Rivero A
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():1. PubMed ID: 20116609
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole.
    Kinnari P; Mäkilä E; Heikkilä T; Salonen J; Hirvonen J; Santos HA
    Int J Pharm; 2011 Jul; 414(1-2):148-56. PubMed ID: 21601623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metabolic changes in PI-based HAART. Change to atazanavir: continued effectiveness with improved lipid profile].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():42-3. PubMed ID: 19024917
    [No Abstract]   [Full Text] [Related]  

  • 12. Concurrent atazanavir and voriconazole in a patient with multidrug-resistant HIV and a mycetoma.
    Gibson JN; Fulco PP
    AIDS; 2011 Oct; 25(16):2054-6. PubMed ID: 21997493
    [No Abstract]   [Full Text] [Related]  

  • 13. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
    Regazzi M; Villani P; Gulminetti R; Cusato M; Brandolini M; Tinelli C; Barassi A; Maserati R; Sighinolfi L; D'Arminio Monforte A; Melzi D'Eril GV
    Ther Drug Monit; 2011 Jun; 33(3):303-8. PubMed ID: 21544015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.
    Rodríguez Nóvoa S; Barreiro P; Rendón A; Barrios A; Corral A; Jiménez-Nacher I; González-Lahoz J; Soriano V
    Clin Infect Dis; 2006 Jan; 42(2):291-5. PubMed ID: 16355344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
    Fabbiani M; Bracciale L; Doino M; D'Avino A; Marzocchetti A; Navarra P; Cauda R; De Luca A; Di Giambenedetto S
    J Infect; 2011 Apr; 62(4):319-21. PubMed ID: 21329725
    [No Abstract]   [Full Text] [Related]  

  • 17. Atazanavir gets FDA Advisory Committee's thumbs-up.
    IAPAC Mon; 2003 Jun; 9(6):120. PubMed ID: 12951939
    [No Abstract]   [Full Text] [Related]  

  • 18. New atazanavir capsule approved.
    AIDS Patient Care STDS; 2006 Nov; 20(11):813. PubMed ID: 17134355
    [No Abstract]   [Full Text] [Related]  

  • 19. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials.
    Balas F; Manzano M; Horcajada P; Vallet-Regí M
    J Am Chem Soc; 2006 Jun; 128(25):8116-7. PubMed ID: 16787058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat.
    Wang XQ; Fan JM; Liu YO; Zhao B; Jia ZR; Zhang Q
    Int J Pharm; 2011 Oct; 419(1-2):339-46. PubMed ID: 21843612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.